United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Endeavor BioMedicines reveals encouraging results for ENV-101 in Phase 2a idiopathic pulmonary fibrosis trial Endeavor BioMedicines, a clinical-stage biotechnology company, has announced encouraging results from their completed Phase 2a clinical trial of… byPallavi MadhirajuMay 20, 2024